116287-14-0

Basic information

• Product Name: Lanperisone
• Synonyms: Lanperisone;(R)-2-methyl-3-(pyrrolidin-1-yl)-1-(4-(trifluoromethyl)phenyl)propan-1-one
• CAS NO: 116287-14-0
• Molecular Formula: C15H18F3NO
• Molecular Weight: 285.307
• Mol File: 116287-14-0.mol

Chemical Properties

• Boiling Point: 360°Cat760mmHg
• Flash Point: 171.5°C
• Appearance: /
• Density: 1.17g/cm³
• Vapor Pressure: 2.29E-05mmHg at 25°C
• Refractive Index: 1.49
• PKA: 9.62±0.20(Predicted)
• CAS DataBase Reference: Lanperisone(CAS DataBase Reference)
• NIST Chemistry Reference: Lanperisone(116287-14-0)
• EPA Substance Registry System: Lanperisone(116287-14-0)

Safety Data

• Hazardous Substances Data: 116287-14-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C15H18F3NO/c1-11(10-19-8-2-3-9-19)14(20)12-4-6-13(7-5-12)15(16,17)18/h4-7,11H,2-3,8-10H2,1H3/t11-/m1/s1

Upstream product

• 50-00-0 formaldehyd 
• 711-33-1 4-trifluoromethyl propiophenone 
• 25150-61-2 pyrrolidine hydrochloride 
• 123-75-1 pyrrolidine 
• 107075-67-2 2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino-1-propanone 
• 67081-98-5 (+/-)-1-<4-(trifluoromethyl)phenyl>-1-propanol 
• 455-19-6 4-Trifluoromethylbenzaldehyde 

Downstream Products

• 116287-13-9 (S)-2-methyl-3-pyrrolidino-1-(4-trifluoromethylphenyl)-propan-1-one hydrochloride 
• 116287-13-9 NK433 

Relevant articles and documents

THERAPEUTIC DRUGS FOR POLLAKIURIA AND URINARY INCONTINENCE CONTAINING OPTICAL ACTIVE PROPIOPHENON AND ITS SALTS

Disclosed herein is a therapeutic agent for urinary frequency and incontinence, comprising an optically active propiophenone derivative or a pharmaceutically acceptable salt thereof as an effective ingredient. The therapeutic agent for urinary frequency and incontinence is an oral formulation comprising (-) - (R) -2-methyl-3- (1-pyrrolidinyl) - 4 '-trif luoromethyl-propiophenone hydrochloride as an effective ingredient. Unlike conventional therapeutic agents for urinary frequency and incontinence, the derivative has good therapeutic effects on urinary frequency and incontinence and minimal side effects because it acts on the central nervous system and inhibits micturition hyperreflexia. Thus, the present therapeutic agent can replace conventional therapeutic agents for urinary frequency and incontinence.

Synthesis and activity of 2-methyl-3-aminopropiophenones as centrally acting muscle relaxants

Some novel 2-methyl-3-aminopropiophenones were synthesized and their centrally acting muscle relaxant activities were,evaluated for an inhibitory effect on the flexor reflex in rats. The structure-activity relationships are discussed. In this series 2-methyl-3-pyrrolidino-1-(4-trifluoromethylphenyl)-propan-1-one (28) showed significant centrally acting muscle relaxant activity. In addition, the activities of each enantiomer (28-(S) and (R)) were studied along with their acute toxicities. Compound 28-(R) was found to exhibit more potent activity and weaker acute toxicity than 28-(S). Accordingly, compound 28-(R) (NK433) is under development as a novel centrally acting muscle relaxant.

Derivatives of an aminoketone

A new class of aminoketone derivatives according to the formula: STR1 and certain propiophenone derivatives in particular, corresponding to the formula: STR2 having central muscle relaxant activity.

An optically active propanone derivative and process for producing the same and use thereof

An optically active 2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino-1-propanone, and a process for producing the same is disclosed and use thereof.